GlaxoSmithKline has seen plenty of changes across its executive ranks over the last couple of years as CEO Emma Walmsley took the helm, but they’re still coming.
Monday, the company said Jack Bailey, its U.S. pharma president and a veteran at the drugmaker, would step down at the end of the year. He’ll be succeeded by Maya Martinez-Davis, who currently serves as the president of Merck KGaA’s Latin America pharma business.
In Bailey, GSK will lose an “exceptional leader” who’s spent more than 10 years at Glaxo since joining the company from Eli Lilly, global pharma president Luke Miels said in a statement. But the pharma giant will have time to ease the transition: Martinez-Davis will come on in mid-September before officially taking the baton Jan. 1. Bailey, meanwhile, will stay on as a strategic consultant through 2020.
In Martinez-Davis, GSK is picking up an exec with experience in one of its key focus areas: oncology. After trading away its cancer assets back in early 2015, Walmsley reprioritized the field last year with pipeline moves and a $5.1 billion Tesaro deal agreement. Now, it’ll have an exec on board who in the past has served as both senior vice president of Merck KGaA’s global oncology business and as a regional president of Pfizer’s oncology portfolio in North America.
“As we continue to grow and reshape our business globally, we are pleased to have found a leader in Maya who will bring a valuable U.S. experience and deep therapy area expertise to expanding our specialty care capabilities and market presence,” Miels said.
Bailey is just one in a sea of leaders who have departed the company since previous CEO Andrew Witty first announced his planned exit. Most recently, longtime Chief Financial Officer Simon Dingemans left in May, and next up is chairman Sir Philip Hampton, who will turn the reins over to ex-Novartis and AstraZeneca Chief Financial Officer Jonathan Symonds Aug. 31.
By: Carly Helfand
Source: Fierce Pharma
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”